» Management of Skin Toxicities from MKIs

GI CONNECT has identified the Management of Skin Toxicities from Multikinase Inhibitor Therapies (MKIs) on the ESMO OncologyPRO portal as a practical guide on how to prevent and treat skin toxicities from MKIs

Management of Skin Toxicities from Multi Kinase Inhibitors (MKIs)

Dr.Guillem Argilés (medical oncologist), Paz Fernández Ortega (clinical nurse specialist) and Prof. Siegfried Segaert (dermatologist) updated this helpful resource. With almost 100,000 visits, healthcare professionals continue to value the practical guidance available.

This important resource aims to;

1) Explore the side effects of inhibiting receptor tyrosine kinases (RTK)

2) Provide expert advice on the prophylaxis and treatment of skin toxicities

3) Provide recommendation on how to manage side effects while maintaining treatment with MKIs

Primarily this guidance exists for healthcare professionals and contains information, treatment algorithms and educational materials relating to the management of dermatological side effects in patients treated with MKIs.

However, there is also a helpful section for patients and caregivers on skin, mouth and hair changes that can sometimes occur with this particular type of treatment.

COR2ED have donated this content to ESMO to ensure that the practical guide reflects today's best clinical practice in managing skin toxicities from MKIs.

Dr Guillem Argilés obtained his medical degree at the Vall d’Hebron University Hospital in Barcelona, Spain. He later obtained his M.D., supervised by José Baselga M.D., in 2006 at the same institute. In 2010, he joined the Gastrointestinal Malignancies Division led by Josep Tabernero M.D., Ph.D. Dr Argilés currently works in the Gastrointestinal Malignancies and Developmental Therapeutics Divisions of the same institute, where his research is focused on chemorefractory colorectal cancer, personalized medicine, as well as the molecular biology of colorectal cancer.

Paz Fernández is the Nursing Research Coordinator at the Catalan Institute of Oncology in Barcelona and since 2010, Associated Professor at the Faculty of Medicine and Health Sciences at the University of Barcelona, where she earned her Doctorate in Nursing Sciences and a Bachelor in Clinical Psychology. From 1999 to 2005, Paz has been a member on the Executive Board of EONS (European Oncology Nursing Society), and until 2001, a Board member of SEEO (Spanish Oncology Nursing Society). Paz belongs to the Node of Cancer at Joanna Briggs Institute and to the EANS (European Academy of Nursing Science) scholars group. Her area of expertise is symptoms management in cancer patients, chemoterapy and oral anticancer drugs. In 2014 she received the EONS Lifetime Achievement Award for her 30 years in oncology and professional contribution to the field of oncology nursing.